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Intracellular signalling: The Mad way to do it
Rik Derynck and Ying Zhang
A family of proteins has been identified that transduce
a signal inside cells following binding of a TGF-b family
ligand to its cognate receptor. Like the prototype
Drosophila protein Mad, many members of the family
play key roles in developmental signalling.
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Secreted signalling molecules play key roles in the
development of multicellular organisms. A class of sig-
nalling molecules that figure largely in development is the
transforming growth factor-b (TGF-b) family, members of
which regulate cell growth, differentiation and tissue mor-
phogenesis in species from insects and worms to
mammals. TGF-b itself induces growth arrest in diverse
cell types, including epithelial cells, and the expression of
various proteins, some of which are deposited in the extra-
cellular matrix. TGF-b-related factors include activin and
the bone morphogenetic proteins (BMPs).
TGF-b and related factors signal to their target cells by
interacting with two types of receptor serine/threonine
kinase, which form a heteromeric receptor complex [1,2].
Until recently, little was known about the signaling mecha-
nisms and intracellular effector proteins that mediate the
complex responses following receptor activation. Genetic
studies in the fruitfly Drosophila melanogaster and the nema-
tode Caenorhabditis elegans, as well as complementary bio-
chemical studies, have now identified a set of homologous
proteins which are important intracellular mediators of
responses to TGF-b-related factors, the prototype of which
has been dubbed ‘Mad’ (etymology below).
Mad homologs in flies and worms
The Drosophila gene decapentaplegic (dpp) plays a part in
patterning the dorsal–ventral embryonic axis and the wing
imaginal discs. Its product, Dpp is the Drosophila homolog
of vertebrate BMP-2 and BMP-4. The type II receptor
‘Punt’ and two type I receptors, ‘Thick veins’ and ‘Saxo-
phone’, bind Dpp and generate a signal inside target cells.
Punt acts in concert with Thick veins and both are essen-
tial for dpp-dependent patterning, whereas Saxophone may
cooperate with Punt to interpret peak levels of dpp [3]. 
A genetic screen for enhancers of weak dpp alleles uncov-
ered mothers against dpp (mad) as a maternal-effect gene
that encodes a downstream component required for dpp
signalling [4,5]. The 455 amino-acid protein product of the
mad gene acts downstream from the Dpp receptors, as the
mutant phenotype caused by a constitutively active form
of the Thick veins receptor can be suppressed by mad null
alleles [6,7]. Moreover, overexpression of mad partially
complements dpp deficiencies [7], and expression of dpp
fails to induce responses in mad mutant flies [8]. Mad is
thus a rate-limiting component that is required for Dpp
signalling and acts downstream from the receptors.
A parallel strand to the story stems from genetic studies of
C. elegans development [9,10]. The C. elegans gene daf-4
plays a role in the quiescent ‘dauer’ larval stage, develop-
ment of the male tail and the control of body size. The daf-4
gene product is a receptor serine/threonine kinase for an as-
yet unidentified homolog of BMP-2 and BMP-4 [10]. Three
genes, sma-2, sma-3 and sma-4, function autonomously in
the same cells as daf-4 and are required for daf-4 function
[9]. Sma null alleles confer phenotypes resembling the daf-4
mutant phenotype; they cannot be rescued by ectopic daf-4
expression, so their products act downstream from the Daf-
4 receptor [9]. The Sma-2, Sma-3 and Sma-4 proteins are
structurally related to each other and to Drosophila Mad.
Thus, structurally related intracellular proteins are required
to signal inside cells in response to receptor binding by
BMP-2/-4 homologs in both Drosophila and C. elegans.
Sequences and activities of Smads
The identification of Mad in Drosophila and of the related
Sma proteins in C. elegans has sparked frenzied attempts to
identify vertebrate homologs and evaluate their function.
Five vertebrate Mad genes have already been identified
(Fig. 1). Their identification in different laboratories has
resulted in a diversity of names; we shall refer to them as
Smad-1 to Smad-5, based on a recent simplification of the
nomenclature. All Mad homologs have two highly con-
served domains in the amino- and carboxy-terminal thirds
of the protein, separated by a proline-rich sequence of
variable sequence and length. The inactivating mutations
in the Drosophila and C. elegans genes cluster towards the
end of the carboxy-terminal domain [5,9]. Smads fall into
two classes based on structural characteristics: Sma-4 [9]
and Smad-4/DPC-4, first identified as a candidate tumor
suppressor [11], are larger than the other Smads and have
a characteristic insert in their carboxy-terminal domains.
Smads from different species show a high level of
sequence conservation — for example, human and
Xenopus Smad-1s are 95 % identical.
The biological activities of overexpressed Smads provide
evidence that they are effector proteins in receptor
signaling and that different Smads induce distinct
responses that mimic the effects of different ligands. Over-
expression of Xenopus or human Smad-1, or Drosophila Mad
induces ventral mesoderm in Xenopus embryos, similarly to
BMP-2/-4 [8,12,13]. Overexpression of Xenopus Smad-1 also
reverses the neuralizing effect of a dominant-negative form
of a BMP-2/-4 receptor [12,14] and inhibits the induction of
dorsal mesoderm by activin [13]. Thus, Smad-1 could be
considered as an effector of BMP-2/-4 signalling, just as
Mad is an effector of Dpp signalling in Drosophila. In con-
trast, overexpression of Smad-2 [12,13] induces dorsal
mesoderm, similarly to activin, suggesting that it acts as an
effector of activin signalling. And Smad-3, but not Smad-1
or Smad-2, induces TGF-b-like responses [15].
It has also been shown that normal, ligand-induced
responses can be inhibited by overexpressing functionally
inactive Smads. Indeed, overexpression of a mutant
Smad-3, truncated in a similar fashion to the product of a
Drosophila mad null allele, inhibits the natural TGF-b
response. This inhibitory effect of truncated Smad-3, but
not truncated Smad-1/-2, together with the activity of
overexpressed Smad-3, strongly implies that Smad-3 is an
effector of the TGF-b response [15]. The distinct
responses to different Smads, mimicking the responses to
BMP-2/-4, activin or TGF-b, thus indicate a selectivity in
their activities and suggest that different Mads may
mediate BMP-2/-4, activin or TGF-b receptor signaling.
These findings suggest that the signal from a given type of
receptor can be transmitted via a single Smad. There may,
however, be important functional interactions between dif-
ferent Smads, and the structurally distinct Smad-4 may play
an important role in receptor signalling. Indeed, Smad-4
strongly synergizes with Smad-3 in inducing TGF-b
responses, whereas other Smads do not. Furthermore, over-
expression of truncated Smad-4, like truncated Smad-3,
inhibits TGF-b signalling, suggesting that Smad-3 and
Smad-4 cooperate and are both required to mediate TGF-b
signalling [15]. Smad-4 may also cooperate with Smad-1
and Smad-2 to mediate BMP-2/-4 or activin signalling.
Regulation of Smad activities
Smads are targets for serine and threonine phosphorylation,
and Smad phosphorylation may correlate with receptor acti-
vation. Smad-1 is phosphorylated in cells expressing type I
and type II BMP-2/-4 receptors, and this phosphorylation is
increased by BMP-2. An inactive mutant Smad-1 is not
phosphorylated under these conditions [6]. However,
TGF-b also induces phosphorylation of endogenous
Smad-1 and Smad-5 [16,17], and activation of TGF-b recep-
tors also increases phosphorylation of Smad-2 [18], which
has been implicated in activin signalling [12,19]. Receptor
activation thus results in Smad phosphorylation, but this
may not be as selective as suggested by the activities of the
overexpressed Smads. Some of the analyses may be compli-
cated by cell-type differences, overexpression of receptors
or Smads and the phosphorylation of endogenous Mad.
It is not yet clear whether the phosphorylation of specific
site(s) correlates with Smad activity or whether Smads are
targets for the receptor kinase itself or an intermediate
kinase. Co-immunoprecipitation data suggest that Smad-3
associates with the receptor complex, though not necessar-
ily directly [15]. Furthermore, Smad-3 is efficiently phos-
phorylated by the type I, but not the type II receptor, in
vitro [15]. Some Smads might thus associate with activated
receptor complexes and be phosphorylated by them. In
contrast, Smad-4, which synergizes with Smad-3, and pos-
sibly other Smads, does not associate with the TGF-b
receptor complex and is not phosphorylated [15].
Although overexpressed Smads induce ligand-indepen-
dent responses, their activities are regulated by functional
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Figure 1
Alignment of Smads showing their percentage
identity and indicating the conserved amino-
terminal (yellow) and carboxy-terminal (blue)
domains. Vertical green lines between nodes
identify possibly orthologous lineages. In
some cases, there is evidence that the Smad
transduces the intracellular signal
downstream of a particular receptor, the
ligands for which are indicated on the right.
References: Drosophila Mad [5]; C. elegans
Sma-2, Sma-3 and Sma-4 [9]; Smad-1 [13];
MADR1 [6]; Xmad-1 [12,14]; hMAD-1 [15];
dwarfin-A (DWF-A) [16]; Bsp-1 [17]; Smad-
2/MADR2 [18,19]; JV18-1 [29]; hMAD-2
[15]; Xmad-2 [12]; Smad-3/hMAD-3 [15];
Smad-4/DPC-4/hMAD-4 [11,15]; Smad-
5/dwarfin-C (DWF-C) [16].
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receptors. Thus, the synergistic activity of Smad-3 and
Smad-4 is greatly enhanced by co-expressing type II and
type I TGF-b receptors, but not by either receptor alone or
by kinase-inactive receptors, and is strongly decreased by
overexpressing truncated type II or type I receptors which
are dominant-negative inhibitors of receptor function [15].
These observations do not rule out the possibility that
Smads have an intrinsic activity independent of receptor
function, which can be enhanced by phosphorylation.
However, Smad activities have not been evaluated in cells
lacking both type II and type I receptors, nor have the
activities of Smad mutants lacking specific phosphorylation
sites been tested.
The subcellular localization of Smads is also regulated.
They are present in both cytosol and nucleus [6,8,12,13],
but treatment of cells with BMP-2/-4 increases the accu-
mulation of Smad-1 in the nucleus [6,13]. Furthermore,
Smad-2 is predominantly cytosolic in the absence of activin
and mostly nuclear in the presence of activin [19]. These
findings suggest that receptor activation results in translo-
cation of Smads from the cytoplasm into the nucleus.
Whether this translocation requires phosphorylation is not
yet clear.
In the nucleus, Smads may play a role in transcriptional
activation of specific genes. A carboxy-terminal segment
of Smad-1 or Smad-4 functions as a transcriptional activat-
ing region when fused to a DNA-binding domain. The
carboxy-terminal truncation that inactivates Smad-1 abol-
ishes transcriptional activity in this assay. With full-length
Smad-1, transcriptional activity depends on receptor co-
expression and stimulation with BMP-4 [13]. It thus
seems that the conserved carboxy-terminal region of
Smads has transcriptional activation potential that is nor-
mally repressed by the rest of the protein, and that this
repression is relieved after receptor activation, perhaps as
a result of Smad phosphorylation.
Taken together, the current findings invite a model of
receptor signalling and Smad function, much of which
requires experimental evaluation (Fig. 2). In this model,
ligand binding to the heteromeric receptor complex
induces phosphorylation of type I receptors by the consti-
tutively active type II receptors. Receptor activation then
results in phosphorylation of receptor-associated Smads.
The phosphorylated Smads may then cooperate with
Smad-4, which is not associated with the receptor or phos-
phorylated by it. The cooperativity of Smads with Smad-4,
which may require a physical association, may be a general
prerequisite for receptor signalling; C. elegans, for example,
contains a Smad-4-like protein, Sma-4, and sma-4 and
sma-2 null mutants have similar phenotypes [9]. The acti-
vated, heteromeric Smad complex may be translocated
into the nucleus to function as a transcriptional activator.
Homologs of the Drosophila proteins Schnurri, Sal and
Salr, which act downstream from Dpp and resemble tran-
scription factors, may associate with the Smad complex
[20–22]. The genes for plasminogen activator inhibitor I
and the cyclin-dependent kinase (Cdk) inhibitor p15 may
be direct targets for transcriptional activation, as their tran-
scription is strongly upregulated by TGF-b. Increased
expression of p15 would inhibit Cdk4 and Cdk6, arresting
the cell cycle in late G1 phase. This model resembles the
activation of cytokine-induced responses by ‘signal trans-
ducers and activators of transcription’ (STATs; see Fig. 2).
Smads as tumor suppressors
The effector role of Smads in TGF-b signalling allows
them to function as tumor suppressors. Tumor cells have
often acquired resistance to the growth inhibitory effect of
TGF-b, which may confer a distinct advantage in tumor
Figure 2
a) A working model of how Smads fit into
signal transduction pathways downstream of
receptors for TGF-b-related ligands; this is
still rather speculative and requires
considerable experimental evaluation. (b) For
comparison, the better-established pathway of
signal transduction by STATs.
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progression towards malignancy [23]. In principle, resis-
tance could be achieved by functional inactivation of any
essential signalling intermediate. For example, the tumor
suppressor retinoblastoma protein, pRB, functions as a
growth suppressor that prevents the G1- to S-phase cell-
cycle transition [24], and its inactivation might prevent
TGF-b-induced growth arrest [25,26]. The anti-prolifera-
tive response to TGF-b could be prevented more directly
by inactivating the TGF-b receptors or downstream medi-
ators such as the Smads. Accordingly, many colon carcino-
mas have non-signalling, mutant type II TGF-b receptors,
and re-introduction of wild-type receptors confers TGF-b-
induced growth inhibition and decreases the tumorigenic
phenotype [27]. So, the type II receptor should also be
considered as a tumor suppressor. Smad-4/DPC-4 was ini-
tially identified as a candidate tumor suppressor in pancre-
atic carcinomas, in which the DPC-4 gene is often deleted
or inactivated [11]. Smad-4 and Smad-2 mutations have also
been found in colorectal carcinomas [6,28,29]. Given that
Smad-4 has an essential role in TGF-b signalling , presum-
ably its inactivation prevents TGF-b responsiveness and
growth inhibition [15]. The inactivation of different com-
ponents of the TGF-b signalling pathway(s) might greatly
contribute to the progression towards malignancy.
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